Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
It is very uncertain whether comparison 1: PERPHENAZINE changes acceptability of treatment ‐ leaving the study early due to any reason compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · patients with schizophrenia
It is very uncertain whether horticultural therapy plus standard care changes satisfaction with treatment Leaving the study early compared with standard care alone (very low certainty).
1 finding from 1 review
Acceptability (of intervention): Leaving the studies early – any reason Loss to · patients with treatment compliance for people with serious mental illness
1 finding from 1 review
Acceptability (of intervention): Leaving the studies early – any reason Loss to · patients with treatment compliance for people with serious mental illness
INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) FOR PROMPTING/SUPPORT… showed no clear difference in acceptability (of intervention): Leaving the studies early – any… compared with STANDARD CARE (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).
1 finding from 1 review
Leaving the study early (2‐10 weeks) vs. standard higher dose (> 7.5‐15 mg/day) · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. standard higher dose (>… compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early · people with the acute phase of schizophrenia
It is very uncertain whether STANDARD LOWER DOSE (> 3 to 7.5 mg/day) changes leaving the study early (2‐10 weeks) vs. high dose (> 15‐35 mg/day) compared with OTHER DOSES (very low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
HALOPERIDOL showed no clear difference in leaving the study early compared with PLACEBO (moderate certainty).
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (CRISIS INTERVENTION) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (GRADUALLY INCREASED DRUG‐FREE PERIODS) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether INTERMITTENT (DRUG HOLIDAY) changes leaving the study early/ loss to compared with MAINTENANCE THERAPY (very low certainty).
2 findings from 1 review
Leaving the study early/ loss to · patients with schizophrenia
It is very uncertain whether ANY INTERMITTENT DRUG TECHNIQUE changes leaving the study early/ loss to compared with PLACEBO (very low certainty).
1 finding from 1 review
Clinical global response‐leaving the study early (short term) · patients with schizophrenia
DANCE THERAPY showed no clear difference in clinical global response‐leaving the study early (short term) compared with STANDARD CARE (moderate certainty).
1 finding from 1 review
Clinical global response‐leaving the study early (long term) · patients with schizophrenia
DANCE THERAPY showed no clear difference in clinical global response‐leaving the study early (long term) compared with STANDARD CARE (low certainty).
1 finding from 1 review
Leaving the study early · patients with schizophrenia
Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).
1 finding from 1 review
Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis
1 finding from 1 review
Adverse effects: Leaving the study early · people with psychosis
1 finding from 1 review
Leaving the study early · patients with chronic mental illnesses
It is very uncertain whether life skills programme changes leaving the study early compared with standard care (very low certainty).
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE (very low certainty).
1 finding from 1 review